Tim Cortese

The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.

In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.

Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.

T-DXd improved OS, PFS, ORR, and DOR vs ramucirumab plus paclitaxel in the second-line treatment of HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

After a lack of significant topline overall survival data from the phase 3 HERTHENA-Lung02 trial, the application for HER3-DXd in NSCLC was withdrawn.

A Chinese phase 2 trial found that anti-GPRC5D CAR T-cell therapy elicited an ORR of 84% in patients with relapsed or refractory multiple myeloma.

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.

In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.

Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

The 1.5T Elekta Unity MR-Linac demonstrated lower rates of erectile dysfunction with neurovascular sparing vs without in patients with intermediate-risk prostate cancer.

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.

The FDA refuses to file the sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with papillary disease without carcinoma in situ.

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

The FDA requires additional confirmatory evidence to progress the application for TLX101-CDx in this glioma indication.

Results from the phase 2/3 trial also show a favorable OS trend for KN026 with chemotherapy vs placebo with chemotherapy in HER2-positive gastric cancer.

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

This study conducted within the phase 3 AML17 and AML19 trials revealed an OS rate of 69% in patients monitored for MRD and 58% in those not monitored.

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.